Targeting depression: Primary care tips and tools

,; ,

Behavioral Health

Targeting depression: Primary care tips and tools

J Fam Pract. 2017 April;66(4):244-249

PDF Download

References

1. National Institute of Mental Health. Major depression among adults. National Institute of Mental Health Web site. Available at: http://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml. 2014. Accessed June 22, 2016.

2. Cameron C, Habert J, Anand L, et al. Optimizing the management of depression: primary care experience. Psychiatry Res. 2014;220:S45-S57.

3. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:629-640.

4. Schotte CK, Van Den Bossche B, De Doncker D, et al. A biopsychosocial model as a guide for psychoeducation and treatment of depression. Depress Anxiety. 2006;23:312-324.

5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013:160-161.

6. Sadock BJ, Sadock VA. Kaplan and Sadock’s Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:830-834.

7. Fishbain DA, Cutler R, Rosomoff HL, et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain. 1997;13:116-137.

8. Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003;327:1144-1146.

9. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-613.

10. US Preventive Services Task Force. Depression in adults: Screening. US Preventive Services Task Force Web site. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/depression-in-adults-screening. Accessed March 13, 2017.

11. Thombs BD, Ziegelstein RC. Does depression screening improve depression outcomes in primary care? BMJ. 2014;348:g1253.

12. Siu AL, Bibbins-Domingo K, Grossman DC, et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:380-387.

13. Sadock BJ, Sadock VA. Kaplan and Sadock’s Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:543.

14. Gould MS, Marrocco FA, Kleinman M, et al. Evaluating iatrogenic risk of youth suicide screening programs: a randomized controlled trial. JAMA. 2005;293:1635-1643.

15. Eynan R, Bergmans Y, Antony J, et al. The effects of suicide ideation assessments on urges to self-harm and suicide. Crisis. 2014;35:123-131.

16. Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61:714-719.

17. Ishak WW, Ha K, Kapitanski N, et al. The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry. 2011;19:277-289.

18. Raddock M, Martukovich R, Berko E, et al. 7 tools to help patients adopt healthier behaviors. J Fam Pract. 2015;64:97-103.

19. Castonguay LG, Constantino MJ, Holtforth MG. The working alliance: Where are we and where should we go? Psychotherapy (Chic). 2006;43:271-279.

20. Greenberg RP, Constantino MJ, Bruce N. Are patient expectations still relevant for psychotherapy process and outcome? Clin Psychol Rev. 2006;26:657-678.

21. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-459.

22. Sadock BJ, Sadock VA. Kaplan and Sadock’s Synopsis of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:558.

23. Linde K, Kriston L, Rücker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2015;13:69-79.

24. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. 2010. Available at: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed December 23, 2016.

25. Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic treatment for treatment-resistant depression: A systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18:pyv060.

26. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163:1519-1530; quiz 1665.

27. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. Am J Psychiatry. 2016;173:575-587.

28. Dodd S, Horgan D, Malhi GS, et al. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord. 2005;89:1-11.

29. Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166:2314-2321.

30. Papakostas GI, Fava M. Pharmacotherapy for Depression and Treatment-Resistant Depression. Hackensack, NJ: World Scientific. 2010:4.

› CASE

Based on further conversation with Mr. M, you learn that he actually began exhibiting symptoms of depression (anhedonia, poor concentration, insomnia) years before he lost his job, but that he had considered the symptoms “normal” for his age. He reports that he didn’t want to socialize with others anymore and harbors feelings of worthlessness. You tell him that you believe he is suffering from MDD and talk to him about some options for treatment. You decide together to begin a trial of escitalopram 10 mg/d, as it was covered by his insurance, has minimal adverse effects, and was a good match for his symptoms. You also educate and instruct Mr. M on self-management goals such as limiting alcohol intake, eating at least 2 meals a day, walking with his wife each evening, and following a regular sleep schedule. You discuss a safety plan with Mr. M, should his depressive symptoms worsen. Specifically, you tell him that if he begins to have suicidal intentions or plans, he should call 911 or go to the nearest emergency department.

Mr. M returns 4 weeks later and reports that his mood has slightly improved, as evidenced by a brighter affect and increased energy, so you increase the dose of escitalopram to 20 mg/d. At his third visit 4 weeks later, Mr. M discloses a remote history of trauma and current intermittent heavy drinking. After offering support and education and discussing his options, you refer Mr. M to a counselor in your clinic through a “warm handoff” (the counselor is brought briefly into the current session with the patient to meet and set up an appointment). During this time, he is given information about an outpatient substance abuse treatment group.

Mr. M’s PHQ-9 improves by 8 points by his fourth visit 4 weeks later. He reports that he is still taking the escitalopram and you recommend he continue to take it. Mr. M tells you he’s been seeing the counselor at your clinic every other week and that he has begun attending meetings with the substance abuse group. He also says that he and his wife go out for walks now and then. Mr. M says he feels as though he is a failure, prompting you to recommend that he explore the cognitive distortions (ie, inaccurate thoughts that reinforce negative feelings) with his therapist.

You schedule another appointment with Mr. M in 3 months to keep track of his progress. Fortunately, Mr. M’s therapist works in the same clinic as you, so you can contact her to discuss his progress with therapy.

CORRESPONDENCE
Michael Raddock, MD, 2500 MetroHealth Drive, Cleveland, OH 44109; mraddock@metrohealth.org.